Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Get Rating) saw a large growth in short interest during the month of August. As of August 31st, there was short interest totalling 1,090,000 shares, a growth of 17.6% from the August 15th total of 927,200 shares. Based on an average trading volume of 293,600 shares, the days-to-cover ratio is currently 3.7 days. Currently, 3.4% of the company’s shares are sold short.
Analyst Upgrades and Downgrades
A number of research firms have recently issued reports on MRNS. StockNews.com downgraded Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, August 12th. JMP Securities reiterated a “buy” rating and issued a $22.00 price target on shares of Marinus Pharmaceuticals in a research note on Thursday, June 9th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $32.17.
Institutional Investors Weigh In On Marinus Pharmaceuticals
A number of institutional investors have recently modified their holdings of MRNS. Quantbot Technologies LP acquired a new stake in shares of Marinus Pharmaceuticals in the first quarter valued at $40,000. Amalgamated Bank acquired a new stake in shares of Marinus Pharmaceuticals in the first quarter valued at $56,000. PDT Partners LLC acquired a new stake in shares of Marinus Pharmaceuticals in the second quarter valued at $63,000. Laurion Capital Management LP acquired a new stake in shares of Marinus Pharmaceuticals in the second quarter valued at $74,000. Finally, Price T Rowe Associates Inc. MD grew its stake in Marinus Pharmaceuticals by 39.5% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 15,600 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 4,417 shares in the last quarter. 77.43% of the stock is owned by institutional investors and hedge funds.
Marinus Pharmaceuticals Price Performance
Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) last posted its earnings results on Thursday, August 11th. The biopharmaceutical company reported ($1.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.13). Marinus Pharmaceuticals had a negative net margin of 386.11% and a negative return on equity of 266.12%. The business had revenue of $1.79 million during the quarter, compared to analysts’ expectations of $2.25 million. Equities analysts expect that Marinus Pharmaceuticals will post -1.9 EPS for the current year.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
- Get a free copy of the StockNews.com research report on Marinus Pharmaceuticals (MRNS)
- Adobe Perfects the Art of the Faceplant for Investors
- Tax Credits are the Incentives in the Inflation Reduction Act
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
- Is There a Cure for What is Ailing Teladoc Stock?
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.